NO980218L - p16 ekspresjonskonstruksjoner og deres anvendelse i kreftbehandling - Google Patents

p16 ekspresjonskonstruksjoner og deres anvendelse i kreftbehandling

Info

Publication number
NO980218L
NO980218L NO980218A NO980218A NO980218L NO 980218 L NO980218 L NO 980218L NO 980218 A NO980218 A NO 980218A NO 980218 A NO980218 A NO 980218A NO 980218 L NO980218 L NO 980218L
Authority
NO
Norway
Prior art keywords
expression constructs
expression
cancer treatment
transcript
replication
Prior art date
Application number
NO980218A
Other languages
English (en)
Other versions
NO980218D0 (no
Inventor
Xiaomei Jin
Jack Roth
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of NO980218D0 publication Critical patent/NO980218D0/no
Publication of NO980218L publication Critical patent/NO980218L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Det beskrives en rekke genetiske konstruksjoner som vil finne både in vitro og in vivo anvendelse på området tumorbiologi og cancerterapi. Spesielt tilveiebringes ekspresjonskonstruksjoner som inneholder en p16-kodende region og andre nødvendige regulatorelementer for ekspresjonen av et p16-transkript. En versjon av ekspresjonskonstruksjonen er en replikasjons-defekt adenoviral vektor. Det tilveiebringes også fremgangsmåter for transformasjon av cellelinjer og inhibering av cancercelleproliferasjon.
NO980218A 1995-07-17 1998-01-16 p16 ekspresjonskonstruksjoner og deres anvendelse i kreftbehandling NO980218L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50288195A 1995-07-17 1995-07-17
PCT/US1996/011787 WO1997003635A2 (en) 1995-07-17 1996-07-17 p16 EXPRESSION CONSTRUCTS AND THEIR APPLICATION IN CANCER THERAPY

Publications (2)

Publication Number Publication Date
NO980218D0 NO980218D0 (no) 1998-01-16
NO980218L true NO980218L (no) 1998-03-16

Family

ID=23999797

Family Applications (1)

Application Number Title Priority Date Filing Date
NO980218A NO980218L (no) 1995-07-17 1998-01-16 p16 ekspresjonskonstruksjoner og deres anvendelse i kreftbehandling

Country Status (15)

Country Link
US (1) US6251871B1 (no)
EP (1) EP0839207A2 (no)
JP (1) JPH11510380A (no)
KR (1) KR19990029028A (no)
CN (1) CN1203632A (no)
AU (1) AU724324B2 (no)
BR (1) BR9609853A (no)
CA (1) CA2227193A1 (no)
CZ (1) CZ15498A3 (no)
HU (1) HUP9901908A3 (no)
NO (1) NO980218L (no)
NZ (1) NZ313828A (no)
PL (1) PL324750A1 (no)
SK (1) SK6598A3 (no)
WO (1) WO1997003635A2 (no)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6689561B1 (en) * 1994-04-14 2004-02-10 The Regents Of The University Of California Tumor suppressor gene and methods for detection of cancer, monitoring of tumor progression and cancer treatment
US7163925B1 (en) * 1995-07-17 2007-01-16 Board Of Regents, The University Of Texas System p16 expression constructs and their application in cancer therapy
GB9519275D0 (en) 1995-09-21 1995-11-22 Univ Dundee Substances and their therapeutic use
EP0862445B2 (en) † 1995-10-06 2017-03-22 Arch Development Corporation Combination of herpes simplex virus and chemotherapy for treating cancer
CA2283090A1 (en) * 1997-02-20 1998-08-27 Hepavec Aktiengesellschaft Fur Gentherapie Method for induction of apoptotic cell death in malignant cells, through reduction of the rb to apoptosis inducing proteins ratio
HUP0001550A3 (en) 1997-03-14 2001-02-28 Unilever Nv Frozen food product
US6489305B1 (en) 1998-05-08 2002-12-03 Canji, Inc. Methods and compositions for the treatment of ocular diseases
KR19990086165A (ko) * 1998-05-26 1999-12-15 성재갑 Cdk４ 의 저해제인 p16의 카복시말단이 절단된 결손형cδp１６ 단백질, 그의 유전자
US6420345B1 (en) * 1999-03-01 2002-07-16 Cell Genesys, Inc. Methods and reagents for inhibiting angiogenesis
US20040266834A1 (en) * 1999-10-14 2004-12-30 Copland John A. Thiazolidinediones alone or in cabination with other therapeutic agents for cancer therapy
US7223406B2 (en) 2000-07-21 2007-05-29 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
AU2001278981A1 (en) * 2000-07-21 2002-02-05 Tom F Lue Prevention and treatment of sexual arousal disorders
US20040005294A1 (en) * 2002-02-25 2004-01-08 Ho-Young Lee IGFBP-3 in the diagnosis and treatment of cancer
US20030219696A1 (en) * 2002-05-23 2003-11-27 Moreland Gerald W. Method and apparatus for preventing backflow in dental saliva evacuators
US7465442B2 (en) 2003-11-24 2008-12-16 Canji, Inc. Reduction of dermal scarring
MX2007002169A (es) 2004-08-27 2007-08-14 Cyclacel Ltd Inhibidores de cdk de purina y pirimidina y su uso para el tratamiento de enfermedades inmunes.
US7695965B2 (en) * 2006-03-02 2010-04-13 Cythera, Inc. Methods of producing pancreatic hormones
CN103293308B (zh) * 2013-05-24 2014-11-26 尉军 一种检测肿瘤标志物p16抗原表位氨基酸序列及应用
CN104558147B (zh) * 2015-01-20 2017-11-07 刘林林 一种检测宫颈癌标志物cdkn2a抗原表位多肽及应用
CA2986032A1 (en) 2015-05-14 2016-11-17 Expression Pathology, Inc. Srm/mrm assay for the fibroblast growth factor receptor 2 (fgfr2) protein
JP6600697B2 (ja) * 2015-05-22 2019-10-30 エクスプレッション、パソロジー、インコーポレイテッド サイクリン依存性キナーゼ阻害剤２Ａ（ｐ１６）タンパク質のためのＳＲＭ／ＭＲＭアッセイ

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0273085A1 (en) 1986-12-29 1988-07-06 IntraCel Corporation A method for internalizing nucleic acids into eukaryotic cells
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
US6211334B1 (en) 1992-10-16 2001-04-03 Cold Spring Harbor Cell-cycle regulatory proteins, and uses related thereto
JP3485186B2 (ja) 1992-10-16 2004-01-13 コールド・スプリング・ハーバー・ラボラトリー サイクリン複合体の転位およびそれに関連する使用
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
MY119195A (en) * 1993-12-30 2005-04-30 Shell Int Research Lightweight, wide-bodied compliant tower.
CN1128049A (zh) 1994-03-18 1996-07-31 犹他大学研究基金会 多肿瘤抑制因子基因种系突变及检测该基因癌肿倾向性的方法
WO1995025429A1 (en) 1994-03-18 1995-09-28 Myriad Genetics, Inc. Mts gene, mutations therein, and methods for diagnosing cancer using mts gene sequence
US6689561B1 (en) * 1994-04-14 2004-02-10 The Regents Of The University Of California Tumor suppressor gene and methods for detection of cancer, monitoring of tumor progression and cancer treatment
KR970702915A (ko) 1994-04-29 1997-06-10 린다 버겐 종양 세포의 치료 감응성 향상 방법(Enhancing The Sensitivity of Tumor Cells to Therapies)
DE19501073A1 (de) * 1995-01-16 1996-08-01 Nova C O R D Ag Bildverarbeitungsverfahren zur Ermittlung der Strukturfestigkeit eines Prüfobjektes mit diffus streuender Oberfläche
AU5297496A (en) * 1995-02-17 1996-09-04 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods of preparation and use of recombinant adenoviral vectors
US5672508A (en) 1996-01-23 1997-09-30 Mitotix, Inc. Inhibitors of cell-cycle progression, and uses related thereto
CN1248731C (zh) 1997-02-18 2006-04-05 坎吉公司 肿瘤抑制基因与化学药物在制备用于治疗肿瘤的药物组合物中的联合应用

Also Published As

Publication number Publication date
SK6598A3 (en) 1998-09-09
NZ313828A (en) 1999-02-25
EP0839207A2 (en) 1998-05-06
NO980218D0 (no) 1998-01-16
AU6647896A (en) 1997-02-18
WO1997003635A3 (en) 1997-05-15
WO1997003635A2 (en) 1997-02-06
CZ15498A3 (cs) 1998-07-15
CA2227193A1 (en) 1997-02-06
HUP9901908A3 (en) 2000-02-28
JPH11510380A (ja) 1999-09-14
KR19990029028A (ko) 1999-04-15
BR9609853A (pt) 1999-10-13
CN1203632A (zh) 1998-12-30
AU724324B2 (en) 2000-09-14
HUP9901908A2 (hu) 1999-09-28
US6251871B1 (en) 2001-06-26
PL324750A1 (en) 1998-06-08

Similar Documents

Publication Publication Date Title
NO980218L (no) p16 ekspresjonskonstruksjoner og deres anvendelse i kreftbehandling
AR001830A1 (es) Terapia genetica por medio del uso de vectores adenovirales
MX9708401A (es) Genes reguladores de la cromatina.
FI973467A0 (fi) DNA-molekyylejä, valmistus ja käyttö geeniterapiassa
DK1992695T3 (da) Lectin-transmembran-antigen af type C udtrykt i human prostatacancer og avendelser deraf
EP1126034A3 (en) Coding sequences of the human BRCA1 gene
WO1997012986A3 (en) Non-group c adenoviral vectors
EP1017797A4 (en) NON-ORIGINATING PRIMATE LENTIVIRUS VECTORS AND PACKAGING SYSTEMS
NO975557L (no) Immortalisering og dissimortalisering av celler
MX9801264A (es) Control de la expresion del gen de cd44 para uso terapeutico.
ATE205532T1 (de) Zellzyklus-unabhängige, gliomaoberflach- spezifische, menschliche monoklonale antikörper
WO1998037185A3 (en) Vectors for controlled gene expression
WO2003008578A3 (en) Reagents and methods for identifying gene targets for treating cancer
AU5318496A (en) Adenovirus vectors for gene therapy
EP1070122A4 (en) INDUCTION OF THE EXPRESSION OF APOPTOTIC OR CYTOTOXIC GENES BY CO-SUPPORT OF ADENOVIRAL MEDIATED GENES
DE59604375D1 (de) Leberspezifischer adenovirus-expressionsvektor
WO1995034669A3 (en) Retroviral gene therapy vectors and therapeutic methods based thereon
NO20002412L (no) FremgangsmÕte for behandling av tumorer og tumorceller ved anvendelse av ex vivo aktiverte T celler
CY1111522T1 (el) 84p2a9: ειδικη σε προστατη και ορχεις πρωτεϊνη που εκφραζεται σε υψηλο βαθμο στον προστατικο καρκινο
ATE248914T1 (de) Allogenes vakzin und synthesemethode für selbiges
DE69737597D1 (de) Vektoren zur inhibierung von viralem und tumorwachstum
PT870015E (pt) Novas xilanases os genes que as codificam e as suas utilizacoes
ATE297409T1 (de) In krebszellen überexprimiertes genprodukt
AU4644297A (en) Reversal of cancer phenotype by inhibiting expression of prostate tumor inducing gene
EP0993468A4 (en) PREPARATIONS AND METHOD FOR ACTIVATING CERTAIN GENES

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application